CanSino's DTcP vaccine tops older DTaP shot on pertussis antibody response
A Phase 3 trial in Chinese infants found CanSino's three-component pertussis vaccine produced stronger anti-PT and anti-FHA antibody responses than a co-purified DTaP comparator, with similar rates of adverse reactions.
Executive Summary
- A randomized, blinded Phase 3 trial in young infants found a three-component acellular pertussis vaccine produced markedly stronger antibody responses against two key pertussis antigens than an existing co-purified vaccine, while causing adverse reactions at a similar rate.
- The trial compared the new formulation against both a licensed co-purified DTaP vaccine and a combination vaccine that also covers polio and Hib, isolating how the antigen preparation method affects immune response rather than testing a new mechanism.
- The antibody gap on filamentous hemagglutinin was large enough that the trial's authors frame it as support for moving China's routine immunization program away from co-purified pertussis vaccines toward component-based ones.
- The result lands in a vaccine field with an established manufacturing distinction, co-purified versus component-based acellular pertussis antigens, rather than a novel biological target, and fits a broader pattern of component vaccines showing cleaner immunogenicity profiles.
What was tested
The trial evaluated a novel diphtheria, tetanus, and acellular pertussis vaccine with three pertussis components, adsorbed (DTcP), against China's existing co-purified DTaP vaccine and a separate DTaP-IPV-Hib combination vaccine. The registered primary endpoints covered two domains: the incidence of adverse reactions within 30 days of each dose, and antibody seroconversion rates and geometric mean concentrations against pertussis toxin, filamentous hemagglutinin, pertactin, diphtheria toxoid, and tetanus toxoid, measured 30 days after the three-dose primary series. The trial enrolled 2,520 infants overall and completed in April 2025. Immunogenicity+1Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.Jul 22, 2026A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)NCT05951725
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was done
This was a partially randomized, blinded, controlled Phase 3 trial that enrolled 1,140 infants at 3 months of age, assigned to a three-dose primary series at 3, 4, and 5 months, comparing the DTcP vaccine against a licensed co-purified DTaP vaccine and a DTaP-IPV-Hib vaccine. Immunogenicity was assessed by anti-PT, anti-FHA, anti-pertactin, anti-diphtheria-toxoid, and anti-tetanus-toxoid seroconversion and geometric mean concentration 30 days after completion of the primary series, while safety was tracked as adverse reactions within 30 days of each dose. ImmunogenicityImmunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.Jul 22, 2026
The result
Both the DTcP and co-purified DTaP vaccines produced fewer overall adverse reactions than the DTaP-IPV-Hib comparator, at 17.99% and 18.08% respectively versus 21.96%. On immunogenicity, the DTcP vaccine demonstrated non-inferiority and superiority over co-purified DTaP for anti-PT and anti-FHA responses. The anti-FHA seroconversion rate reached 98.16% for DTcP against 14.29% for co-purified DTaP, and the anti-FHA geometric mean concentration was 108.28 for DTcP versus 10.69 for the comparator. Anti-PT geometric mean concentration was 85.10 for DTcP versus 49.86 for co-purified DTaP (p<0.001) and 74.25 for the DTaP-IPV-Hib arm (p=0.001). ImmunogenicityImmunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.Jul 22, 2026
Field context
Pertussis vaccine development has accumulated a long track record: trials pairing the pertussis toxin target with pertussis indication span 21 trials across 10 sponsors reaching as high as Phase 4, with none of the eight completed Phase 3 trials in this pairing terminated for failure. Direct comparators tracked in this class include Sanofi's Tdap-IPV vaccine, GlaxoSmithKline's Boostrix, and CanSino's own earlier Tdcp vaccine program, all tested against similar co-purified or component formulations. Against that backdrop, the distinguishing question in this trial was not whether an acellular pertussis vaccine works, but whether a component-based antigen preparation clears a materially higher immunogenicity bar than the co-purified process already in use.
What it changes
The trial's authors describe the data as supporting a shift in China's immunization strategy from co-purified to component-based acellular pertussis vaccines to address waning immunity amid a pertussis resurgence. The comparison was against a domestic co-purified standard rather than against acellular vaccines used in other markets, so the finding speaks most directly to formulation choice within China's own vaccination program. ImmunogenicityImmunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.Jul 22, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.